Carmolex, Inc., USA, is Pleased to Announce it has Entered into an Agreement with Sanofi in Germany

Share Article

Carmolex's advanced solutions/platform is poised to deliver Sanofi in Germany with a diverse set of high-quality chemotypes, pre-clinical, low molecular weight hits against biologically relevant PPIs; with a hit rate of at least 20%.

Expanding Chemical Space using Multi-Component Reactions

Carmolex, Inc., a small molecule lead generation pharmaceutical service company with advanced solutions for early stage drug discovery, is pleased to announce that it has entered into an agreement with Sanofi in Germany¬. While the full terms of the deal are not public, Carmolex has agreed to develop target-induced molecules by implementing its proprietary technology, and to deliver a diverse set of high-quality pre-clinical small molecules designed to antagonize an undisclosed protein-protein interaction of therapeutic interest.

Carmolex, based in Pittsburgh, Pennsylvania, is a recently launched pharmaceutical service company motivated by the urgent need to address today’s serious imbalance between disease related protein targets and worthwhile small molecule drug starting points. It’s advantage derives from a world-class scientific team and ability to integrate deep knowledge of structural biology, medicinal and computational chemistry.

The AnchorQueryTM platform (developed at the University of Pittsburgh by Drs. Camacho, Doemling and Koes and used under license), in conjunction with the InstantChemTM internal database of 500 multi-component reactions (MCRs), allows Carmolex to efficiently and economically deliver its clients and collaborators with highly targeted, IP protected, small molecule hits against biologically relevant protein/protein interaction targets (PPIs). AnchorQueryTM technology recently allowed Prof. Doemling’s team to successfully design and validate a collection of MDM2-P53 inhibitors representing a more diverse number of chemotypes than those reported by competing pharmaceutical leaders.

Currently, there are only a handful of known low-molecular weight inhibitors for biologically relevant PPI targets. Traditional high-throughput screening (HTS) efforts usually have a very low success rate in delivering hits for such targets because the screening libraries commonly available are historically biased, with compounds derived from previous drug discovery efforts. Carmolex’s technology platform is well poised to overcome this limitation and able to deliver low molecular weight hits against biologically relevant PPIs with a hit rate of at least 20%.

AnchorQueryTM copyrightUniversity of Pittsburgh. Used under license.
InstantChemTM copyrightCarmolex, Inc. 2012

Carmolex, Inc., c/o Rafael Velez, MD, CEO
rafael(dot)velez(at)carmolex(dot)com    
412 223 9772

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Rafael Velez
Visit website

Media

Carmolex, Inc. Logo